Therapeutic Target for Treating Huntington's and Parkinson's Disease

Author: University of Western Ontario
Published: 2014/01/08 - Updated: 2022/01/03
Topic: Clinical Trial Research - Publications List

Page Content: Synopsis - Introduction - Main

Synopsis: Research from Western University has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Huntington's Disease is an inherited neuro-degenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.

Introduction

Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a Huntington's Disease mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted.

Main Item

The research is published online in Human Molecular Genetics.

Huntington's Disease is an inherited neuro-degenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.

Working in the Ferguson lab where Ribeiro was a postdoctoral trainee, the scientists crossed two mouse models. One was a mouse which doesn't have glutamate receptors - they've been knocked out genetically, and the other is a Huntington's Disease mouse model which over-expresses mutant human Huntington protein. They found if they deleted mGluR5, they lost the pathology of Huntington's in the neurons, and they saw improvements in motor behavior which normally would be impaired in these mice.

"What we found was, if we block mGluR5, which is the glutamate receptor we're interested in, the mice become hyper locomotive so they become able to move better than wild type mice suggesting glutamate receptors might be a good target for treating movement disorders such as Parkinson's disease. So that was a bit of a surprise that came out in the study, and we can show that genetically and pharmaceutically," says Ferguson who holds a Canada Research Chair in Molecular Neurobiology.

"And the good thing is, there are mGluR5 antagonists now in stage three clinical trials for diseases such as Fragile X, so it is quite possible these drugs will be available for patients in the future."

Attribution/Source(s): This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by University of Western Ontario and published on 2014/01/08, this content may have been edited for style, clarity, or brevity. For further details or clarifications, University of Western Ontario can be contacted at uwo.ca NOTE: Disabled World does not provide any warranties or endorsements related to this article.